source
- Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitisBoth Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
- Celldex culls eczema study after Phase 2 failureCelldex Therapeutics is dropping its monoclonal antibody as a therapy for eczema after the drug flunked a mid-stage study. The drug, called barzolvolimab, failed to reduce itching in patients with…Endpoints · 36m ago↗ source